2.1
Burosumab (Crysvita, Kyowa Kirin) is indicated for 'the treatment of X‑linked hypophosphataemia in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults'.
2 Information about burosumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for burosumab.
Price
2.3
The list prices per vial of solution for injection are £2,992 for 10 mg/1 ml, £5,984 for 20 mg/1 ml, and £8,976 for 30 mg/1 ml (excluding VAT; BNF online accessed November 2023).
2.4
The company has a commercial arrangement. This makes burosumab available to the NHS with a discount. The size of the discount is commercial in confidence.